Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $152.46, giving the company a market capitalization of 188.3B. It carries a P/E multiple of 22.98 and pays a dividend yield of 2.0%.
On 2026-02-13, Gilead Sciences(GILD) stock moved within a range of $150.82 to $156.42. With shares now at $152.46, the stock is trading +1.1% above its intraday low and -2.5% below the session's peak.
Trading volume for Gilead Sciences(GILD) stock has reached 9.77M, versus its average volume of 8.78M.
The stock's 52-week range extends from a low of $93.37 to a high of $157.29.
The stock's 52-week range extends from a low of $93.37 to a high of $157.29.
GILD News
FDA expands the label for Gilead’s Yescarta CAR T-cell therapy to include relapsed or refractory primary central nervous system lymphoma, the first therapy of i...
Gilead Sciences ((GILD)) has held its Q4 earnings call. Read on for the main highlights of the call. Valentine's Day Sale - 70% Off Unlock hedge fund-level data...
Gilead rises after earnings beat driven by HIV drug sales Gilead rose more than 5% on Wednesday after it reported quarterly earnings and revenue that beat Wall...
Analyst ratings
76%
of 29 ratingsMore GILD News
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences today and set a price target of $160.00. Tyler Van Buren has given his Buy rating d...
Scotiabank analyst Louise Chen raised the firm’s price target on Gilead (GILD) to $177 from $140 and keeps an Outperform rating on the shares. The firm notes Gi...
Gilead Sciences Inc. (NASDAQ:GILD) posted upbeat fourth-quarter earnings but issued weak fiscal 2026 guidance on Tuesday. Gilead reported quarterly earnings of...
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
Gilead Sciences Inc. (NASDAQ:GILD) shares slipped in Tuesday's extended trading after the company released its fourth-quarter earnings report with weak fiscal 2...
(RTTNews) - Gilead Sciences Inc. (GILD) released earnings for its fourth quarter that Increases, from the same period last year The company's bottom line total...
Gilead Sciences posted a profit of $2.18 billion, or $1.74 a share, compared with $1.78 billion, or $1.42 a share, a year earlier. Mike Blake/Reuters Gilead Sc...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.